Cost per dose is an estimate based on the US dose cost but its an unknown and I doubt we'll be told
Announcement's refer to an unmet need in China so no known comparison product/competition in China.
Who pays for it in China? I think that it will mostly be out of pocket. I found this article but not sure on the accuracy :
"The reimbursement rates for cancer treatment are set by the local governments and vary widely due to the differences in the financial situations of each district. For example, in City of Qingdao the municipal healthcare agency reimburses 80% for IMRT treatment"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097739/
I guess it will be dependant on the NMPA label
https://telixpharma.com/wp-content/uploads/2023/01/TLX_Strategic_Licence_and_Partnership_for_Greater_China_Market.pdf
Ann: Telix-Grand Pharma Investor Webcast Notification, page-26
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.85 |
Change
-0.650(3.51%) |
Mkt cap ! $5.973B | |||
| Open | High | Low | Value | Volume |
| $18.29 | $18.40 | $17.78 | $12.04M | 670.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6515 | $17.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.88 | 200 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |